

A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye Disease

NCT07211776

Status	RECRUITING
Phase	Phase 3
Sponsor	Zai Lab (Shanghai) Co., Ltd.
Enrollment	99 participants

Key Eligibility Criteria

Inclusion (4)

- Have moderate to severe TED
- Must meet the clinical diagnosis criteria of active TED
- Must agree to use highly effective contraception as specified in the protocol
- Female TED participants must have a negative serum pregnancy test at screening

Exclusion (4)

- Have received prior treatment with another anti-IGF-1R mAb or anti-thyroid stimulating hormone receptor (TSHR) mAb.
- Have received systemic corticosteroids or steroid eye drops for any condition, or other immunosuppressive drugs for any condition, including TED, or radioactive iodine (RAI) treatment within a certain period prior to first dose.
- Have corneal decompensation in the study eye unresponsive to medical management.
- Have a pre-existing ophthalmic in the study eye which in the opinion of the Investigator, would confound interpretation of the study results.

Locations (27 total)

Site01006, Beijing, China
Site01009, Beijing, China
Site01010, Beijing, China
... and 24 more locations